Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 70, Issue 9, 2011, Pages 1562-1568

  Giles, Jon T ^a   Van Der Heijde, Desiree M ^b   Bathon, Joan M ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEPTIN; PREDNISONE; RESISTIN;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOOT RADIOGRAPHY; HAND RADIOGRAPHY; HIGH RISK PATIENT; HUMAN; JOINT DESTRUCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE;

ADIPOKINES; ADIPONECTIN; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; BIOLOGICAL MARKERS; BODY COMPOSITION; BODY MASS INDEX; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 80051474980     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.150813     Document Type: Article

References (22)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61. (Pubitemid 40852711)
2. Clarke AE, St-Pierre Y, Joseph L, et al. Radiographic damage in rheumatoid arthritis correlates with functional disability but not direct medical costs. J Rheumatol 2001;28:2416-24. (Pubitemid 33031970)
3. Drossaers-Bakker KW, Zwinderman AH, Vliet Vlieland TP, et al. Long-term outcome in rheumatoid arthritis: a simple algorithm of baseline parameters can predict radiographic damage, disability, and disease course at 12-year followup. Arthritis Rheum 2002;47:383-90. (Pubitemid 34856126)
4. Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
5. Tang CH, Chiu YC, Tan TW, et al. Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-kappa B pathway. J Immunol 2007;179:5483-92.
6. Ehling A, Schäffler A, Herfarth H, et al. The potential of adiponectin in driving arthritis. J Immunol 2006;176:4468-78. (Pubitemid 44264427)
7. Ebina K, Fukuhara A, Ando W, et al. Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction. Clin Rheumatol 2009;28:445-51.
8. Giles JT, Allison M, Bingham CO, 3rd, et al. Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis. Arthritis Rheum 2009;61:1248-56.
9. Filková M, Lisková M, Hulejová H, et al. Increased serum adiponectin levels in female patients with erosive compared with non-erosive osteoarthritis. Ann Rheum Dis 2009;68:295-6.
10. Choi HM, Lee YA, Lee SH, et al. Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. Arthritis Res Ther 2009;11:R161.
11. Frommer KW, Zimmermann B, Meier FM, et al. Adiponectin-mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum 2010;62:2886-99.
12. Luo XH, Guo LJ, Xie H, et al. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 2006;21:1648-56. (Pubitemid 44484610)
13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
14. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
15. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
16. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum 2000;43:2751-61. (Pubitemid 32001741)
17. Harris ML, Darrah E, Lam GK, et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum 2008;58:1958-67. (Pubitemid 351988087)
18. Kobayashi H, Giles JT, Polak JF, et al. Increased prevalence of carotid artery atherosclerosis in rheumatoid arthritis is artery-specific. J Rheumatol 2010;37:730-9.
19. Silswal N, Singh AK, Aruna B, et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005;334:1092-101. (Pubitemid 41074686)
20. Bokarewa M, Nagaev I, Dahlberg L, et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005;174:5789-95. (Pubitemid 40593223)
21. Rho YH, Solus J, Sokka T, et al. Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 2009;60:1906-14.
22. Tsao TS, Tomas E, Murrey HE, et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. Different oligomers activate different signal transduction pathways. J Biol Chem 2003;278:50810-17. (Pubitemid 37548930)